Company profilePharmaceutical#3 of 1,318 in Pakistan10 DRAP alerts

Atco Pharma International (Pvt) Ltd

Pharmaceutical company · 598 brands · 498 molecules

Ranked #1 of 58 companies in Skin Conditions

598 registered products 104 pharmaceutical brands 498 distinct molecules 10 DRAP alerts

Company overview

598
registered products
104
pharmaceutical brands
498
distinct molecules
12
therapeutic classes
10
DRAP alerts

Atco Pharma International (Pvt) Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 598 product registrations across 498 distinct molecules. It is the 3rd largest registrant in Pakistan by product count, and ranks 1st of 58 in Skin Conditions. Its portfolio is concentrated in Skin Conditions and Antineoplastics. DRAP has issued 19 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Atco

476 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

245
ceilings with an approval date
9
not revised in 2+ years
2024
oldest approval year
20249
202522
2026214
Longest without revision

Top molecules by brand count

Betamethasone20 brands
Amlodipine18 brands
Eye16 brands
Nutritional Supplement / Multivitamin14 brands
Neomycin11 brands
Empagliflozin10 brands
Clobetasol9 brands
Metformin9 brands
Artemether8 brands
Timolol7 brands

Therapeutic classes

Skin Conditions · 41Antineoplastics · 15Cardiac Care · 11Blood Glucose Lowering Drugs, Excluding Insulin · 11Anti-Infectives · 10Corticosteroid Combinations, Topical · 9Pain Management · 8Gastro · 8Cardiac Therapy · 8Neuro · 7Antithrombotic Agents · 6Eye Conditions · 6

Conditions treated

Eczema/Psoriasis/Dermatitis · 18Acne/Topical · 9Fungal Infection · 7Hypertension · 6Scabies · 5Oral Agents · 5Ors · 4Pain Killers · 4Infection/Allergy · 3High Cholestrol · 3Hyperpigmentation · 3Blood Clot/Thrombotic Disorder · 3

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official408 products · Rs 4.48 – Rs 64,716.02
DVAGO171 products · Rs 19 – Rs 16,500
Servaid146 products · Rs 36.16 – Rs 14,149.6
Median across source: Rs 275

Regulatory record

10 alerts in the DRAP feed we track.

25. Recall Alert (Human) – CDL Declared Substandard products.
2026-05-04
18. Rapid Alert – Spurious TERBIDERM FORTE TABLET (TERBINAFINE 250 mg) & GLANTRIM OPHTHALM
2026-04-14
123. Recall Alert (Class-I) – Drug Products (Human) Substandard – Gligit Baltistan.
2025-12-18
119. Recall Alert (Class-II) – Drug Products (Human) Substandard -DTL Punjab
2025-12-16
RAPID ALERT – CRACKDOWN AGAINST UNLICENSED/UNAUTHORIZED MANUFACTURERS
2025-08-11
Recall Alert: Substandard Product “Sterile Water for Injection 5ml” Batch No. 224 Mfg. By
2025-01-06
Recall Alert: Drug Product; Water for Injection (Batch 989) by Zafa Pharmaceutical Pvt Ltd
2024-06-10
Rapid Alert: Drug Product; Falsified Risek 40mg Injection identified in the Market
2024-03-27

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.121 shared molecules
VALOR PHARMACEUTICALS115 shared molecules
NEUTRO PHARMA (PVT) LTD.114 shared molecules
Genix Pharma Private Limited106 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NABIQASIM INDUSTRIES (PVT) LTD. holds 132 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAgomelatine
BIO LABS (PVT) LTD. holds 85 molecules not in this portfolio
000 I.UAprepitantAremetherArtesunateAscorbic AcidAzathioprine
Wilshire Laboratories (Private) Limited holds 83 molecules not in this portfolio
Acyclovir SodiumAlfacalcidolAmoxicillinAmoxycillinAmoxycillin BaseAnastrozole

Get the full profile for Atco

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.